SATSUMA PHARMACEUTICALS INC's ticker is STSA and the CUSIP is 80405P107. A total of 37 filers reported holding SATSUMA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $5,541 | -44.9% | 7,932 | -29.1% | 0.00% | – |
Q4 2022 | $10,065 | -99.2% | 11,183 | -95.0% | 0.00% | – |
Q3 2022 | $1,342,000 | +31.4% | 223,816 | -9.3% | 0.00% | – |
Q2 2022 | $1,021,000 | +2072.3% | 246,692 | +1891.9% | 0.00% | – |
Q1 2022 | $47,000 | -80.9% | 12,385 | -77.4% | 0.00% | – |
Q4 2021 | $246,000 | -48.2% | 54,720 | -46.4% | 0.00% | – |
Q3 2021 | $475,000 | -80.9% | 102,090 | -71.0% | 0.00% | – |
Q2 2021 | $2,484,000 | -27.2% | 352,453 | -38.9% | 0.00% | -100.0% |
Q1 2021 | $3,410,000 | -25.5% | 577,022 | -41.9% | 0.00% | 0.0% |
Q4 2020 | $4,580,000 | +378.1% | 993,623 | +303.4% | 0.00% | – |
Q3 2020 | $958,000 | +609.6% | 246,335 | +5155.7% | 0.00% | – |
Q2 2020 | $135,000 | +48.4% | 4,687 | +10.4% | 0.00% | – |
Q1 2020 | $91,000 | -22.2% | 4,246 | -28.5% | 0.00% | – |
Q4 2019 | $117,000 | +5750.0% | 5,936 | +5836.0% | 0.00% | – |
Q3 2019 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 3,118,761 | $14,533,000 | 3.83% |
Ghost Tree Capital, LLC | 904,225 | $4,214,000 | 1.23% |
RA Capital Management | 5,914,252 | $27,560,000 | 0.38% |
Vivo Capital, LLC | 1,232,394 | $5,743,000 | 0.26% |
Nan Fung Group Holdings Ltd | 142,900 | $666,000 | 0.21% |
Ikarian Capital, LLC | 629,384 | $2,934,000 | 0.21% |
NEA Management Company, LLC | 3,142,958 | $14,646,000 | 0.17% |
SAMLYN CAPITAL, LLC | 1,716,067 | $7,998,000 | 0.11% |
TPG Group Holdings (SBS) Advisors, Inc. | 1,885,939 | $8,788,000 | 0.09% |
GSA CAPITAL PARTNERS LLP | 90,665 | $422,000 | 0.04% |